GlassScriptPhysician profile
Eunice Song
NPI 1487018016
$3,894.21
in general payments reported to CMS, 2019-2025
20 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.71 · 2022: $241 · 2023: $734 · 2024: $1,192 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,563.98 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $678.02 | 2023-2025 | Skyrizi, Botox |
| Incyte Corporation | $398.69 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $362.08 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $297.33 | 2022-2025 | Absorica Ld, Winlevi, Blu-U |
| Janssen Biotech, INC. | $271.38 | 2022-2025 | Tremfya |
| Amgen INC. | $260.58 | 2022-2025 | Otezla, Enbrel, Otezla |
| Organon LLC | $255.30 | 2025 | Vtama |
| Dermavant Sciences, INC. | $202.97 | 2023-2024 | Vtama |
| Lilly USA, LLC | $199.83 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $196.32 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $192.41 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $176.83 | 2023-2025 | |
| Pfizer INC. | $152.13 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $69.13 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $67.44 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $27.83 | 2024 | Vyjuvek |
| Biofrontera INC. | $22.97 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| E.R. Squibb & Sons, L.L.C. | $22.86 | 2022 | |
| Ucb, INC. | $22.42 | 2023 | Bimzelx |
| Allergan, INC. | $17.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.